Author Archives: Millie Nelson

Lonza to expand US and EU CGT lab space

Lonza will expand its cell and gene therapy (CGT) development laboratories in the US at its Houston, Texas facility and in Europe at its plant in Geleen, The Netherlands. Swiss contract development manufacturing organization (CDMO) Lonza says the expansion in Houston will include viral vector-based process development and analytical development laboratories. In addition to its Houston expansion, the firm claims it will more than double its European process development laboratory space in Geleen, The Netherlands. The CDMO will add 4,500…

Landmark Bio opens advanced therapy manufacturing plant in MA

Academia-industry joint venture firm Landmark Bio says the recently opened Watertown, Massachusetts facility offers a one-stop-shop for manufacturing solutions. Harvard University, MIT, Fujifilm Diosynth Biotechnologies, Alexandria Real Estate Equities, and Cytiva – the founders of Landmark Bio – collectively invested $75 million to support construction staff and early client services for the 44,000 square-foot Watertown facility that will carry out development, manufacturing, and testing of cell and gene therapies in the area. Other collaborating institutions include Beth Israel Deaconess Medical…

Andelyn opens CGT manufacturing plant in Ohio

CDMO Andelyn Biosciences has opened a clinical and commercial manufacturing facility in Columbus, Ohio to support cell and gene therapy (CGT) development. Contract development manufacturing organization (CDMO) Andelyn has opened a manufacturing facility in Ohio, which it has named the Andelyn Corporate Center (ACC). The firm says that the 200,000 square-foot gene therapy production plant has the capability to support any scale of gene therapy viral vector manufacturing. “We built the ACC in response to increasing customer demand for regulatory-compliant, high…

Zip lipped on sustainability but that doesn’t mean biomanufacturers aren’t working on it

According to industry experts at BWB, sustainability should be so ingrained in the industry’s everyday activities that firms should not have to shout about it.  Sustainability is the hot topic of the moment and a continuous talking point in the biopharma industry. Environmental, social, and governance (ESG) documents are published and sent out across the news wires, but more-often-than-not these are seen as box-ticking exercises or examples of ‘greenwashing.’   But last month, GlaxoSmithKline (GSK) launched a sustainability program calling on its…

AAV platform speeds gene therapy programs, says Charles River

Charles River Laboratories has launched its nAAVigation vector platform, which it says has the ability to reduce a gene therapy developers program timeline by 55%. According to Charles River Laboratories (CRL), its nAAVigation platform has been designed using its adeno-associated virus (AAV) vector contract development and manufacturing organization (CDMO) experience. The company claims that its nAAVigation technology removes the need for significant process development by streamlining the pathway to AAV vector production. Additionally, CRL says that the 55% reduction to…

Inceptor and Avectas team to improve CAR-T manufacturing

The collaboration between Inceptor Bio and Avectas will aim to improve the development and production of CAR-T cell therapies for the treatment of solid tumors. Financial details and length of the partnership remain under wraps. However, under the terms of the agreement, Inceptor will use Avectas’ Solupore technology as a substitute to electroporation for engineering T cells with the aim to produce an improved T cell product. In April 2021, Avectas received $8.7 million in funding to develop the cell…

Univercells triples capacity with Nivelles plant completion

Univercells Technologies has completed a €2 million ($1.9 million) expansion of its Nivelles, Belgium site. Work began at the site in December 2020 and Univercells claims the expansion has doubled its overall footprint while tripling its manufacturing capacity at the plant. Furthermore, the firm says that the expansion has enabled it to provide customers with supply chain security “The first phase has provided a larger warehouse storage as well as the ISO 8 clean room space, greatly increasing capacity for…

Forge Bio launches pDNA production to support gene therapy clients

Forge Biologics has launched plasmid DNA (pDNA) manufacturing services to support its AAV clients after closing a $90 million Series C funding round. Gene therapy contract development manufacturing organization (CDMO) Forge Bio completed a $90 million Series C financing round last month, which it said would be used to expand its technologies, manufacturing systems, and cell lines. Now, the firm has said that on the back of the Series C funding round and the US government’s investment of over $2…

BioNTech heads down under to build mRNA plant

BioNTech has entered into a partnership with the State of Victoria, Australia to construct a research and manufacturing center for mRNA-based products in Melbourne. According to the German biopharma company, the center will support “discovery to delivery” of messenger RNA (mRNA) vaccines and therapies. Additionally, as part of the collaboration, BioNTech will construct a BioNTainer facility for clinical scale manufacturing of mRNA-based products and candidates. A BioNTainer is a cleanroom built from six ISO sized containers and consisting of one…

Intravacc bags two intranasal vaccine deals in one week

A $14.6 million contract for its jointly developed gonorrhea vaccine and a partnership with CEPI to advance coronavirus vaccines make a busy week for Intravacc. Dutch firm, Intravacc, and microparticulate immune therapeutics firm Therapyxpartnered in August 2020 to develop NGoXIM, a prophylactic vaccine that treats gonorrhea. This week, the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the firms a contract with base and options that could potentially total…